Document is current

Article History

Received: 22 March 2022

Accepted: 5 July 2022

First Online: 21 July 2022

Declarations

:

: All data were pseudonymised, and the study was approved by the ethics committee of the medical faculty of Heidelberg University Hospital (internal number S-305/2021). The study complies with the Declaration of Helsinki in its current version.

: Not applicable.

: PX: has received personal fees from MSD and OMT outside the submitted work.JM, OJ, RS, CAE, NBe: nothing to declare.BE: received travel fees, consulting fees, speaking fees, and/or honoraria from Actelion, MSD, Bayer and OMT, outside the submitted work.SH: received honoraria for lectures, consultancy, or both from Actelion, AOP, Bayer/MSD, GSK, Novartis, OMT, Pfizer, and United Therapeutics out-side the submitted work.AMM: AMM has received personal fees from Bayer, outside the submitted work.NBl: has received consulting fees, speaking fees and/or honoraria and unallocated funds from Roche out-side the submitted work.HML: has received consulting fees, speaking fees and/or honoraria and unallocated funds for scientific talks and consultations from Abbvie, Astra-Zeneca, Actelion, Alexion, Amgen, Bayer Vital, Baxter, Biogen, Boehringer Ingelheim, BMS, Celgene, Fresenius, Genzyme, GSK, Gilead/Galapagos, Hexal, Janssen-Cilag, Lilly, Medac, MSD, Mundipharm, Mylan, Novartis, octapharm, Pfizer, Roche/Chugai, Sandoz, Sanofi, Shire, SOBI, Thermo Fisher, UCB.EG: has received grants and personal fees from Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House, outside the submitted work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.